Literature DB >> 34272693

Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Nigel J Waters1, R Scott Obach2, Li Di2.   

Abstract

The study of enzyme kinetics in drug metabolism involves assessment of rates of metabolism and inhibitory potencies over a suitable concentration range. In all but the very simplest in vitro system, these drug concentrations can be influenced by a variety of nonspecific binding reservoirs that can reduce the available concentration to the enzyme system(s) under investigation. As a consequence, the apparent kinetic parameters, such as Km or Ki, that are derived can deviate from the true values. There are a number of sources of these nonspecific binding depots or barriers, including membrane permeation and partitioning, plasma or serum protein binding, and incubational binding. In the latter case, this includes binding to the assay apparatus as well as biological depots, depending on the characteristics of the in vitro matrix being used. Given the wide array of subcellular, cellular, and recombinant enzyme systems utilized in drug metabolism, each of these has different components which can influence the free drug concentration. The physicochemical properties of the test compound are also paramount in determining the influential factors in any deviation between true and apparent kinetic behavior. This chapter describes the underlying mechanisms determining the free drug concentration in vitro and how these factors can be accounted for in drug metabolism studies, illustrated with case studies from the literature.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Keywords:  Enzyme kinetics; Free drug hypothesis; Incubational binding; Membrane permeation; Plasma protein binding; Unbound drug concentration

Year:  2021        PMID: 34272693     DOI: 10.1007/978-1-0716-1554-6_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  99 in total

Review 1.  Changes in plasma protein binding have little clinical relevance.

Authors:  Leslie Z Benet; Betty-ann Hoener
Journal:  Clin Pharmacol Ther       Date:  2002-03       Impact factor: 6.875

2.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

3.  Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

Authors:  Jeannine M Margolis; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

Review 4.  Predicting plasma protein binding of drugs--revisited.

Authors:  Nicole A Kratochwil; Walter Huber; Francis Müller; Manfred Kansy; Paul R Gerber
Journal:  Curr Opin Drug Discov Devel       Date:  2004-07

Review 5.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

6.  Constructing plasma protein binding model based on a combination of cluster analysis and 4D-fingerprint molecular similarity analyses.

Authors:  Jianzhong Liu; Liu Yang; Yi Li; Dahua Pan; Anton J Hopfinger
Journal:  Bioorg Med Chem       Date:  2005-10-07       Impact factor: 3.641

7.  Impact of plasma-protein binding on receptor occupancy: an analytical description.

Authors:  Lambertus A Peletier; Neil Benson; Piet H van der Graaf
Journal:  J Theor Biol       Date:  2008-10-02       Impact factor: 2.691

Review 8.  Alpha-1-acid glycoprotein.

Authors:  T Fournier; N Medjoubi-N; D Porquet
Journal:  Biochim Biophys Acta       Date:  2000-10-18

9.  Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.

Authors:  J H Lin; I W Chen; F A deLuna
Journal:  Drug Metab Dispos       Date:  1994 May-Jun       Impact factor: 3.922

10.  Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist.

Authors:  Holly J Clarke; Francine Gregoire; Fang Ma; Robert Martin; Spring Zhao; Brian E Lavan
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.